Price Target Changed • Jul 27
Price target increased by 15% to ₹1,251 Up from ₹1,090, the current price target is an average from 13 analysts. New target price is 22% below last closing price of ₹1,602. Stock is up 80% over the past year. The company is forecast to post earnings per share of ₹26.29 for next year compared to ₹16.47 last year. Tillkännagivande • Jul 27
Laurus Labs Limited Approves the Retirement of Rajesh Koshy Chandy as an Independent Director, Effective July 26, 2026 Laurus Labs Limited informed that the Board of Directors at their meeting held on July 24, 2026, took note of the retirement of Dr. Rajesh Koshy Chandy as an Independent Director of the Company, with effect from close of business hours on July 26, 2026 after completion of his second term as an Independent Director which was from July 27, 2021 to July 26, 2026. The reason for change was retirement after completion of his second term as an Independent Director. New Risk • Jul 26
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk High level of debt (42% net debt to equity). Reported Earnings • Jul 25
First quarter 2027 earnings: EPS and revenues exceed analyst expectations First quarter 2027 results: EPS: ₹6.81 (up from ₹3.02 in 1Q 2026). Revenue: ₹20.4b (up 30% from 1Q 2026). Net income: ₹3.68b (up 125% from 1Q 2026). Profit margin: 18% (up from 10% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 9.6%. Earnings per share (EPS) also surpassed analyst estimates by 34%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 10
Laurus Labs Limited to Report Q1, 2027 Results on Jul 24, 2026 Laurus Labs Limited announced that they will report Q1, 2027 results After-Market on Jul 24, 2026 Reported Earnings • Jun 13
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.1b (up 23% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • May 27
Price target increased by 7.2% to ₹1,044 Up from ₹974, the current price target is an average from 13 analysts. New target price is 24% below last closing price of ₹1,381. Stock is up 126% over the past year. The company is forecast to post earnings per share of ₹20.53 for next year compared to ₹16.47 last year. Reported Earnings • May 05
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: ₹16.47 (up from ₹6.65 in FY 2025). Revenue: ₹68.7b (up 24% from FY 2025). Net income: ₹8.89b (up 148% from FY 2025). Profit margin: 13% (up from 6.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.5%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Declared Dividend • May 02
Final dividend increased to ₹1.20 Dividend of ₹1.20 is 50% higher than last year. Ex-date: 8th May 2026 Payment date: 30th May 2026 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (10% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 20% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • May 01
Laurus Labs Limited Approves second Interim Dividend for Financial Year 2025-26, Payable on or After May 20, 2026 Laurus Labs Limited announced that at the board meeting held on April 30, 2026, approved the payment of second interim dividend of INR 1.20/- (60%) per equity share of INR 2/- each, for the Financial Year 2025-26. Further, pursuant to Regulation 42 of the SEBI Listing Regulations, the company has fixed "May 08, 2026" as the "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2026. Tillkännagivande • Apr 30
Laurus Labs Limited, Annual General Meeting, Jul 02, 2026 Laurus Labs Limited, Annual General Meeting, Jul 02, 2026. Tillkännagivande • Apr 10
Laurus Labs Limited to Report Q4, 2026 Results on Apr 30, 2026 Laurus Labs Limited announced that they will report Q4, 2026 results on Apr 30, 2026 Reported Earnings • Jan 24
Third quarter 2026 earnings: EPS and revenues exceed analyst expectations Third quarter 2026 results: EPS: ₹4.67 (up from ₹1.71 in 3Q 2025). Revenue: ₹17.8b (up 26% from 3Q 2025). Net income: ₹2.52b (up 173% from 3Q 2025). Profit margin: 14% (up from 6.5% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.2%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings. Tillkännagivande • Jan 09
Laurus Labs Limited to Report Q3, 2026 Results on Jan 23, 2026 Laurus Labs Limited announced that they will report Q3, 2026 results on Jan 23, 2026 Declared Dividend • Oct 25
First half dividend of ₹0.80 announced Shareholders will receive a dividend of ₹0.80. Ex-date: 31st October 2025 Payment date: 22nd November 2025 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (13% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 23% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 86% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Price Target Changed • Oct 25
Price target increased by 14% to ₹797 Up from ₹701, the current price target is an average from 14 analysts. New target price is 14% below last closing price of ₹925. Stock is up 99% over the past year. The company is forecast to post earnings per share of ₹13.01 for next year compared to ₹6.65 last year. Reported Earnings • Oct 24
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: ₹3.61 (up from ₹0.37 in 2Q 2025). Revenue: ₹16.5b (up 35% from 2Q 2025). Net income: ₹1.95b (up ₹1.75b from 2Q 2025). Profit margin: 12% (up from 1.6% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Tillkännagivande • Oct 09
Laurus Labs Limited to Report Q2, 2026 Results on Oct 23, 2025 Laurus Labs Limited announced that they will report Q2, 2026 results on Oct 23, 2025 Price Target Changed • Jul 29
Price target increased by 19% to ₹698 Up from ₹586, the current price target is an average from 13 analysts. New target price is 23% below last closing price of ₹909. Stock is up 98% over the past year. The company is forecast to post earnings per share of ₹11.76 for next year compared to ₹6.65 last year. Reported Earnings • Jul 26
First quarter 2026 earnings: EPS and revenues exceed analyst expectations First quarter 2026 results: EPS: ₹3.02 (up from ₹0.23 in 1Q 2025). Revenue: ₹15.8b (up 32% from 1Q 2025). Net income: ₹1.63b (up ₹1.51b from 1Q 2025). Profit margin: 10% (up from 1.0% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) also surpassed analyst estimates by 59%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Tillkännagivande • Jul 09
Laurus Labs Limited to Report Q1, 2026 Results on Jul 25, 2025 Laurus Labs Limited announced that they will report Q1, 2026 results on Jul 25, 2025 Reported Earnings • Jun 08
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹55.5b (up 10% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.5% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. New Risk • May 20
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Paying a dividend despite having no free cash flows. Tillkännagivande • May 15
Laurus Labs Limited, Annual General Meeting, Jun 26, 2025 Laurus Labs Limited, Annual General Meeting, Jun 26, 2025. Price Target Changed • Apr 26
Price target increased by 8.3% to ₹565 Up from ₹522, the current price target is an average from 14 analysts. New target price is 9.7% below last closing price of ₹625. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹10.60 for next year compared to ₹6.65 last year. Reported Earnings • Apr 25
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹6.65 (up from ₹2.98 in FY 2024). Revenue: ₹56.3b (up 12% from FY 2024). Net income: ₹3.58b (up 123% from FY 2024). Profit margin: 6.4% (up from 3.2% in FY 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 7.2%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Tillkännagivande • Apr 24
Laurus Labs Limited Approves Interim Dividend for Financial Year 2024 - 2025, Payable on or After May 20, 2025 The Board of Directors of Laurus Labs Limited at their meeting held on April 24, 2025 approved for the payment of 2nd Interim Dividend of INR 0.80/- (40%) per equity share of INR 2/- each for the Financial Year 2024 - 2025. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "May 09, 2025" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after May 20, 2025. Tillkännagivande • Apr 10
Laurus Labs Limited to Report Q4, 2025 Results on Apr 24, 2025 Laurus Labs Limited announced that they will report Q4, 2025 results on Apr 24, 2025 Price Target Changed • Jan 27
Price target increased by 14% to ₹512 Up from ₹448, the current price target is an average from 14 analysts. New target price is approximately in line with last closing price of ₹535. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹5.85 for next year compared to ₹2.98 last year. Reported Earnings • Jan 25
Third quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2025 results: EPS: ₹1.71 (up from ₹0.43 in 3Q 2024). Revenue: ₹14.2b (up 19% from 3Q 2024). Net income: ₹923.0m (up 299% from 3Q 2024). Profit margin: 6.5% (up from 1.9% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Tillkännagivande • Jan 06
Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025 Laurus Labs Limited announced that they will report Q3, 2025 results on Jan 24, 2025 Declared Dividend • Oct 26
First half dividend of ₹0.40 announced Dividend of ₹0.40 is the same as last year. Ex-date: 6th November 2024 Payment date: 23rd November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (33% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 281% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Oct 25
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: EPS: ₹0.37 (down from ₹0.69 in 2Q 2024). Revenue: ₹12.2b (flat on 2Q 2024). Net income: ₹198.4m (down 46% from 2Q 2024). Profit margin: 1.6% (down from 3.0% in 2Q 2024). Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) also missed analyst estimates by 63%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Tillkännagivande • Oct 24
Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025 The Board of Directors of the Laurus Labs Limited at their meeting held on October 24, 2024 have approved for the payment of Interim Dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2024- 2025. The Company has fixed November 06, 2024 as Record Date for determining the eligibility of the Shareholders. The Dividend will be paid within 30 days of declaration. Tillkännagivande • Oct 17
Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024 Laurus Labs Limited announced that they will report Q2, 2025 results on Oct 24, 2024 Tillkännagivande • Oct 03
Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director Laurus Labs Limited passed a resolution through Postal Ballot on October 3, 2024, appointment of Mr. Ramesh Subrahmanian as a Non-executive Independent Director of the Company. Approval of members for appointment of Mr. Ramesh Subrahmanian as an Independent Director, who was appointed as additional director in category of Independent Director on July 25, 2024. Appointment is effective from July 25, 2024, for a tenure of 5 years. The company confirm that Mr. Ramesh Subrahmanian meets the criteria for independence as required under Section 149(6) of the Companies Act, 2013 and the rules made thereunder and Regulation 16(1)(b) of the Listing Regulations and that he is not debarred from holding the office of director by virtue of any order of SEBI or any other such authority. Mr. Ramesh Subrahmanian holds a bachelor's degree in Commerce from the University of Mumbai. He is also a certified Chartered Accountant from the Institute of Chartered Accountants in England & Wales. He has about 32 years of experience in pharmaceuticals, medical devices and speciality chemicals including immense years of experience with Sanofi and its predecessor companies (Aventis, HMR and Hoechst AG). He is also the founder and director of Alchemy Advisors, an advisory firm based in Singapore. Mr. Ramesh Subrahmanian is not related to any Director of the Company. Reported Earnings • Jul 26
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: EPS: ₹0.23 (down from ₹0.46 in 1Q 2024). Revenue: ₹12.0b (up 1.3% from 1Q 2024). Net income: ₹125.1m (down 50% from 1Q 2024). Profit margin: 1.0% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 89%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jul 22
Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024 Laurus Labs Limited announced that they will report Q1, 2025 results on Jul 25, 2024 Tillkännagivande • Jul 12
Laurus Labs Limited Announces Board Appointments Laurus Labs Limited announced at the AGM held on July 11, 2024, approved Appointment of Mr. Krishna Chaitanya Chava as Executive Director and Mr. Karnam Sekar (DIN 07400094) as Independent Director for a period of 5 years. Reported Earnings • Jun 20
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.4b (down 17% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Post-clinical trial products Pre-registration: 40 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Additional Independent Director Karnam Sekar was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Declared Dividend • Apr 27
Final dividend reduced to ₹0.40 Dividend of ₹0.40 is 67% lower than last year. Ex-date: 8th May 2024 Payment date: 10th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (27% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 216% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Apr 27
Laurus Labs Limited, Annual General Meeting, Jul 11, 2024 Laurus Labs Limited, Annual General Meeting, Jul 11, 2024, at 15:00 Indian Standard Time. Reported Earnings • Apr 26
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: ₹2.98 (down from ₹14.69 in FY 2023). Revenue: ₹50.7b (down 16% from FY 2023). Net income: ₹1.61b (down 80% from FY 2023). Profit margin: 3.2% (down from 13% in FY 2023). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Tillkännagivande • Apr 19
Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024 Laurus Labs Limited announced that they will report Q4, 2024 results on Apr 25, 2024 Reported Earnings • Jan 25
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: ₹0.43 (down from ₹3.78 in 3Q 2023). Revenue: ₹12.0b (down 23% from 3Q 2023). Net income: ₹231.4m (down 89% from 3Q 2023). Profit margin: 1.9% (down from 13% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 79%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Tillkännagivande • Jan 17
Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024 Laurus Labs Limited announced that they will report Q3, 2024 results on Jan 24, 2024 Upcoming Dividend • Oct 26
Upcoming dividend of ₹0.40 per share at 0.4% yield Eligible shareholders must have bought the stock before 02 November 2023. Payment date: 19 November 2023. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%). Price Target Changed • Oct 24
Price target increased by 7.2% to ₹371 Up from ₹346, the current price target is an average from 12 analysts. New target price is approximately in line with last closing price of ₹362. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₹6.57 for next year compared to ₹14.69 last year. Reported Earnings • Oct 21
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: ₹0.69 (down from ₹4.33 in 2Q 2023). Revenue: ₹12.3b (down 22% from 2Q 2023). Net income: ₹369.5m (down 84% from 2Q 2023). Profit margin: 3.0% (down from 15% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 74%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Tillkännagivande • Oct 21
Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023 Laurus Labs Limited announced that Board of Directors of the Company in their meeting held on October 20, 2023 have approved for the payment of interim dividend of INR 0.40/- (20%) per equity share of INR 2/- each, for the Financial Year 2023-24. Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed "October 30, 2023" as "Record Date" for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 09, 2023. Tillkännagivande • Oct 14
Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023 Laurus Labs Limited announced that they will report Q2, 2024 results on Oct 20, 2023 Tillkännagivande • Sep 12
Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million. Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million on September 11, 2023. Pursuant to the above acquisition, the stake of Laurus Labs in Laurus Bio shall reach to 87.58% on fully diluted basis (including outstanding ESOPs and the Share Warrants). Laurus Bio has revenue of INR 1,286.26 million, EBITDA of INR 369 million, total assets of INR 1,982.54 million, total equity of INR 481.64 million and net income of INR 141.9 million as of March 31, 2023. The Board of Directors of Laurus Labs have accorded its final approval for acquisition. Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹392, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 95% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹190 per share. New Risk • Jul 28
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 9.9% Last year net profit margin: 16% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Dividend is not well covered by cash flows (dividend per share is over 28x cash flows per share). Profit margins are more than 30% lower than last year (9.9% net profit margin). Reported Earnings • Jul 28
First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023) First quarter 2024 results: EPS: ₹0.46 (down from ₹4.68 in 1Q 2023). Revenue: ₹11.9b (down 23% from 1Q 2023). Net income: ₹248.5m (down 90% from 1Q 2023). Profit margin: 2.1% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jun 24
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.4b (up 22% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 39 Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jun 01
Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million. Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million on May 31, 2023. Post the completion of the deal, Laurus Labs’ stake in ImmunoACT will increase to 33.86%. In related transaction some of the Promoters and senior management of Laurus Labs would also invest approximately INR 40 million to purchase 0.54% stake. Transaction is expected to complete in approximately one month. Upcoming Dividend • May 03
Upcoming dividend of ₹1.20 per share at 0.6% yield Eligible shareholders must have bought the stock before 10 May 2023. Payment date: 27 May 2023. Payout ratio is a comfortable 14% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%). Price Target Changed • Apr 30
Price target decreased by 11% to ₹382 Down from ₹430, the current price target is an average from 10 analysts. New target price is 24% above last closing price of ₹308. Stock is down 47% over the past year. The company is forecast to post earnings per share of ₹12.56 for next year compared to ₹14.69 last year. Reported Earnings • Apr 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: ₹14.69 (down from ₹15.42 in FY 2022). Revenue: ₹60.5b (up 23% from FY 2022). Net income: ₹7.90b (down 4.5% from FY 2022). Profit margin: 13% (down from 17% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.4%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Feb 01
Price target decreased by 10% to ₹470 Down from ₹523, the current price target is an average from 11 analysts. New target price is 40% above last closing price of ₹335. Stock is down 36% over the past year. The company is forecast to post earnings per share of ₹17.01 for next year compared to ₹15.42 last year. Reported Earnings • Jan 31
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: EPS: ₹3.78 (up from ₹2.87 in 3Q 2022). Revenue: ₹15.4b (up 50% from 3Q 2022). Net income: ₹2.03b (up 32% from 3Q 2022). Profit margin: 13% (down from 15% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.4%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jan 22
Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023 Laurus Labs Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 30, 2023 Tillkännagivande • Nov 25
Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited Laurus Labs Limited announced that it has entered into a security purchase agreement for the issuance of 740,000 equity shares at a price of INR 52.70 per share for gross proceeds INR 38,998,000 on November 23, 2022. The transaction will include participation from Ethan Energy India Private Limited. Price Target Changed • Nov 16
Price target decreased to ₹561 Down from ₹619, the current price target is an average from 11 analysts. New target price is 22% above last closing price of ₹462. Stock is down 4.7% over the past year. The company is forecast to post earnings per share of ₹19.27 for next year compared to ₹15.42 last year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Head of Quality & Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Oct 28
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in 2023 has deteriorated. 2023 revenue forecast decreased from ₹68.3b to ₹63.9b. EPS estimate also fell from ₹22.34 per share to ₹19.27 per share. Net income forecast to grow 31% next year vs 32% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹619 to ₹561. Share price fell 8.8% to ₹445 over the past week. Upcoming Dividend • Oct 27
Upcoming dividend of ₹0.80 per share Eligible shareholders must have bought the stock before 03 November 2022. Payment date: 20 November 2022. Payout ratio is a comfortable 12% but the company is paying out more than the cash it is generating. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (0.9%). Price Target Changed • Oct 26
Price target decreased to ₹574 Down from ₹619, the current price target is an average from 11 analysts. New target price is 27% above last closing price of ₹453. Stock is down 21% over the past year. The company is forecast to post earnings per share of ₹19.34 for next year compared to ₹15.42 last year. Tillkännagivande • Oct 22
Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022 The board of directors of Laurus Labs Limited in their meeting held on October 21, 2022 have approved for the payment of interim dividend of INR 0.80 (40%) per equity share of INR 2 each, for the financial year 2022-2023. The company has fixed November 04, 2022 as record date for determining the eligibility of the Shareholders. The dividend amount will be paid on or after November 15, 2022. Reported Earnings • Oct 22
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: ₹4.33 (up from ₹3.76 in 2Q 2022). Revenue: ₹15.8b (up 31% from 2Q 2022). Net income: ₹2.33b (up 15% from 2Q 2022). Profit margin: 15% (down from 17% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Oct 14
Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022 Laurus Labs Limited announced that they will report Q2, 2023 results at 12:15 PM, Indian Standard Time on Oct 21, 2022 Reported Earnings • Jul 28
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: EPS: ₹4.68 (up from ₹4.50 in 1Q 2022). Revenue: ₹15.4b (up 20% from 1Q 2022). Net income: ₹2.51b (up 4.1% from 1Q 2022). Profit margin: 16% (down from 19% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.6%. Earnings per share (EPS) also surpassed analyst estimates by 8.4%. Over the next year, revenue is forecast to grow 33%, compared to a 12% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has increased by 99% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 20
Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022 Laurus Labs Limited announced that they will report Q1, 2023 results on Jul 27, 2022 Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹444, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹298 per share. Reported Earnings • Jun 09
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.4b (up 2.5% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Post-clinical trial products Pre-registration: 34 Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 34%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 102% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • May 03
Upcoming dividend of ₹1.20 per share Eligible shareholders must have bought the stock before 10 May 2022. Payment date: 28 May 2022. Payout ratio is a comfortable 13% but the company is paying out more than the cash it is generating. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.9%). Reported Earnings • Apr 29
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Full year 2022 results: EPS: ₹15.42 (down from ₹18.36 in FY 2021). Revenue: ₹49.5b (up 2.9% from FY 2021). Net income: ₹8.28b (down 16% from FY 2021). Profit margin: 17% (down from 20% in FY 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Over the next year, revenue is forecast to grow 23%, compared to a 12% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has increased by 94% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Executive Director Lakshmana Rao Chunduru was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 22
Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022 Laurus Labs Limited announced that they will report Q4, 2022 results on Apr 28, 2022 Major Estimate Revision • Feb 03
Consensus revenue estimates fall by 14% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from ₹55.7b to ₹47.9b. EPS estimate fell from ₹19.51 to ₹15.40 per share. Net income forecast to grow 18% next year vs 21% growth forecast for Pharmaceuticals industry in India. Consensus price target down from ₹607 to ₹563. Share price rose 11% to ₹526 over the past week. Price Target Changed • Feb 02
Price target decreased to ₹563 Down from ₹607, the current price target is an average from 11 analysts. New target price is 7.1% above last closing price of ₹526. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹15.40 for next year compared to ₹18.36 last year. Reported Earnings • Jan 28
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: EPS: ₹2.87 (down from ₹5.09 in 3Q 2021). Revenue: ₹10.3b (down 20% from 3Q 2021). Net income: ₹1.54b (down 44% from 3Q 2021). Profit margin: 15% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 37%. Over the next year, revenue is forecast to grow 30%, compared to a 13% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Nov 10
Upcoming dividend of ₹0.80 per share Eligible shareholders must have bought the stock before 17 November 2021. Payment date: 27 November 2021. Trailing yield: 0.4%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.8%). Reported Earnings • Nov 01
Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: ₹12.0b (up 5.7% from 2Q 2021). Net income: ₹2.02b (down 17% from 2Q 2021). Profit margin: 17% (down from 21% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has increased by 89% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹537, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 696% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹557 per share. Recent Insider Transactions • Sep 22
Insider recently sold ₹7.9m worth of stock On the 17th of September, Vijaya Suryadevara sold around 12k shares on-market at roughly ₹658 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹970m more than they bought in the last 12 months. Recent Insider Transactions • Sep 11
Insider recently sold ₹3.2m worth of stock On the 6th of September, Sreelakshmi Gogireddy sold around 5k shares on-market at roughly ₹649 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹99m. Insiders have been net sellers, collectively disposing of ₹959m more than they bought in the last 12 months. Recent Insider Transactions • Sep 04
Insider recently sold ₹3.6m worth of stock On the 31st of August, Yalamanchili Rama sold around 6k shares on-market at roughly ₹657 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹858m more than they bought in the last 12 months. Recent Insider Transactions • Aug 13
Insider recently sold ₹1.0m worth of stock On the 9th of August, Madhuveer Yadavalli sold around 1k shares on-market at roughly ₹701 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹250m. Insiders have been net sellers, collectively disposing of ₹788m more than they bought in the last 12 months. Price Target Changed • Aug 04
Price target increased to ₹561 Up from ₹512, the current price target is an average from 8 analysts. New target price is 13% below last closing price of ₹646. Stock is up 214% over the past year. Reported Earnings • Jul 30
First quarter 2022 earnings released: EPS ₹4.50 (vs ₹3.21 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹12.8b (up 32% from 1Q 2021). Net income: ₹2.41b (up 41% from 1Q 2021). Profit margin: 19% (up from 18% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 85% per year whereas the company’s share price has increased by 90% per year. Price Target Changed • Jul 12
Price target increased to ₹506 Up from ₹470, the current price target is an average from 8 analysts. New target price is 25% below last closing price of ₹677. Stock is up 443% over the past year. Tillkännagivande • Jul 03
Laurus Labs Limited Receives the License to Manufacture and Market 2-Deoxy-D-Glucose (2DG) in India Laurus Labs Limited announces that it has received the license from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorization (EUA) for 2DG. Reported Earnings • Jun 24
Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹48.1b (up 70% from FY 2020). Net income: ₹9.84b (up 285% from FY 2020). Profit margin: 20% (up from 9.0% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 18 Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has increased by 90% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • May 23
Insider recently bought ₹4.0m worth of stock On the 21st of May, Satish Adewar bought around 8k shares on-market at roughly ₹486 per share. In the last 3 months, they made an even bigger purchase worth ₹6.4m. Insiders have collectively bought ₹92m more in shares than they have sold in the last 12 months. 
